The DOI matches its Crossref record.
Basic Fibroblast Growth Factor Prevents Thalamic Degeneration after Cortical Infarction
Open accessAbstract
In the focal infarction model of the rat middle cerebral artery (MCA), the thalamus of the occluded side becomes gradually atrophic, mainly because of retrograde degeneration. We determined whether basic fibroblast growth factor (bFGF) administered intracisternally could prevent this thalamic atrophy. We occluded the left MCA through a small cranial opening, and animals were then divided into two groups. One group received intra-cisternal injections of recombinant bFGF (1 μg dissolved in 0.1 ml of saline with 2% rat serum) starting 1 day after occlusion and repeated once a week to a total dose of 4 μg by four injections. The other group received vehicle solution by the same schedule. The animals were perfused and fixed at 28 days after occlusion, and histological examination was made at the level of the caudoputamen and thalamus. In the bFGF-treated rats, the area of the posterior ventral thalamus of the occluded side was 93% of that of the contralateral side, i.e., significantly larger than in the normal saline-treated rats (75%, p < 0.01). The infarction size was not statistically different in the two groups. Microscopic observation indicated that normal-saline-treated animals showed shrinkage and disappearance of thalamic neurons, whereas bFGF-treated groups showed preservation of thalamic neurons. Computerized analysis of the cell size substantiated this observation. To assess the effect of bFGF on astrocytes, bFGF or vehicle solution was injected into normal rats, and their histology was evaluated at 1, 2, and 4 weeks after injection. The bFGF-injected group showed a significant increase in glial fibrillary acidic protein-positive astrocytes in the brain tissue facing the ventriculocisternal system. The results suggest that bFGF prevents retrograde degeneration of thalamic neurons by working directly as a neurotrophic factor of these neurons or by activating astrocytes located in the thalamocortical pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Drug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994
Pardridge, W. M. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.013 · Cited by 1,191
Brain Plasticity and Stroke Rehabilitation: The Willis Lecture
Johansson, B. B. (2000) · Stroke · doi:10.1161/01.str.31.1.223 · Cited by 562
CSF, blood-brain barrier, and brain drug delivery
Pardridge, W. M. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1171315 · Cited by 508
Strategy for effective brain drug delivery
Alam, M. I., Beg, S., Samad, A., Baboota, S., Kohli, K., Ali, J., Ahuja, A., & Akbar, M. (2010) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2010.05.003 · Cited by 415
Drug delivery to the central nervous system
Nance, E., Pun, S. H., Saigal, R., & Sellers, D. L. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00394-w · Cited by 414
Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain
Pardridge, W. M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00373 · Cited by 405
“The intrathecal route of drug delivery to brain is suitable for treatment of diseases that affect the surface of the brain, such as carcinomatous meningitis, but is not able to deliver drug into the parenchyma of brain without exposing the surface of the brain to high, and generally toxicologic, drug concentrations (Y…”
BackgroundMultiple Molecular Penumbras after Focal Cerebral Ischemia
Sharp, F. R., Lu, A., Tang, Y., & Millhorn, D. E. (2000) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200007000-00001 · Cited by 403
Pardridge, W. M. (1997) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199707000-00001 · Cited by 328
Drug transport in brain via the cerebrospinal fluid.
Pardridge, W. M. (2011) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-8-7 · Cited by 316
MATTSON, M. P., & SCHEFF, S. W. (1994) · Journal of Neurotrauma · doi:10.1089/neu.1994.11.3 · Cited by 309
Novel Pharmacologic Strategies in the Treatment of Experimental Traumatic Brain Injury: 1998
McINTOSH, T. K., JUHLER, M., & WIELOCH, T. (1998) · Journal of Neurotrauma · doi:10.1089/neu.1998.15.731 · Cited by 298
Kawamata, T., Dietrich, W. D., Schallert, T., Gotts, J. E., Cocke, R. R., Benowitz, L. I., & Finklestein, S. P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.15.8179 · Cited by 296
Manipulating Angiogenesis: From Basic Science to the Bedside
Pepper, M. S. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.4.605 · Cited by 261
A Historical Review of Brain Drug Delivery
Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219
Metadata
- Authors
- Yamada, K., Kinoshita, A., Kohmura, E., Sakaguchi, T., Taguchi, J., Kataoka, K., & Hayakawa, T.
- Venue
- Journal of Cerebral Blood Flow & Metabolism
- Publisher
- SAGE Publications
- Published
- 1991-05
- Volume
- 11
- Issue
- 3
- Pages
- 472-478
- ISSN
- 0271-678X (ISSN-L)
- 1559-7016
- OpenAlex
- W2022307512
- Cited by
- 188
- References
- 0
- FWCI
- 6.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.